Chinook Therapeutics, now a part of Novartis, is a clinical-stage biopharmaceutical company based in Vancouver, Canada. Specializing in precision medicines for rare and severe chronic kidney diseases, Chinook is dedicated to discovering, developing, and commercializing innovative treatments.
The company's pipeline includes promising candidates such as zigakibart bion 1301 for patients with IgA nephropathy and CHK 336, with recent milestones including the enrollment of the first patient in the pivotal Phase 3 BEYOND study. Chinook Therapeutics is committed to advancing research and providing patient resources in the field of kidney care.
Generated from their website